Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis

Bivas-Benita, Maytal; Meijgaarden, Krista E. van; Franken, Kees L. M. C.; Junginger, Hans E.; Borchard, Gerrit; Ottenhoff, Tom H. M.; Geluk, Annemieke

doi:10.1016/j.vaccine.2003.09.044

Cited by 176 publications

(71 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, mature DCs also acquire their ability to activate T cells (Banchereau et al, 2000;Mellman & Steinman, 2001). It was shown that chitosan increased DCs maturation (Porporatto et al, 2005), but some studies reported that chitosan has no effect on DCs (Bivas-Benita et al, 2004;Wischke, Borchert, Zimmermann, Siebenbrodt, & Lorenzen, 2006). Our results demonstrated that B-COS treatment enhanced the surface expressions of CD86 and MHCII on SDCs, rather than TLR4 siRNA-transfected SDCs.…”

Section: Discussionmentioning

confidence: 53%

The effects of chitosan oligosaccharide on the activation of murine spleen CD11c+ dendritic cells via Toll-like receptor 4

Dang

Wang

et al. 2011

Carbohydrate Polymers

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 53%

The effects of chitosan oligosaccharide on the activation of murine spleen CD11c+ dendritic cells via Toll-like receptor 4

Dang

Wang

et al. 2011

Carbohydrate Polymers

View full text Add to dashboard Cite

“…[12], [58], [59] and [61] Thus, aerosol delivery of BCG vaccine prepared as a spray-dried nanomicroparticle aerosol, [57], [58] and [59] or liposome, chitosan and PLGA-PEI DNA vaccine [56] and [62] have also been used in mice and guinea pigs to enhance pulmonary anti-microbial activity against M. tuberculosis infection. Aerosol delivery of the BCG nanomicroparticle to normal guinea pigs subsequently challenged with virulent M. tuberculosis significantly reduced bacterial burden and lung pathology both relative to untreated animals and to control animals immunized with the standard parenteral BCG.…”

Section: Developmentmentioning

confidence: 99%

Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells

González-Juarrero

O’Sullivan

2011

Tuberculosis

View full text Add to dashboard Cite

SummaryInhaled therapies in the form of drugs or vaccines for tuberculosis treatment were reported about a decade ago. Experts around the world met to discuss the scientific progress in inhaled therapies at the international symposium "Optimization of inhaled Tuberculosis therapies and implications for host-pathogen interactions" held in New Delhi, India on November 3-5, 2009. The meeting was organized by the Central Drug Research Institute (CDRI) Lucknow, India. The lung is the main route for infection with Mycobacterium tuberculosis bacilli and the primary site of reactivation of latent disease. The only available vaccine BCG is relatively ineffective at preventing tuberculosis disease and current therapy requires prolonged treatment with drugs which results in low patient compliance. Consequently, there is a need to design new vaccines and therapies for this disease. Recently there has been increased interest in the development of inhaled formulations to deliver anti-mycobacterial drugs and vaccines directly to the lung and many of these therapies are designed to target lung macrophages and dendritic cells. However, the development of effective inhaled therapies requires an understanding of the unique function and immunosuppressive environment of the lung which is driven, in part, by alveolar macrophages and dendritic cells. In this review, we will discuss the role of alveolar macrophages and dendritic cells in the host immune response to M. tuberculosis infection and the ways in which inhaled therapies might enhance the anti-microbial response of phagocytes and boost pulmonary immunity.Keywords: Tuberculosis; Macrophage; Dendritic cell; Inhaled therapy stimulate innate bactericidal responses and/or antigen presenting functions more efficiently and will ameliorate drug toxicity due to reduction in dose/duration of treatment.12 However, the development of successful inhaled therapies in general will depend on the confounding characteristics of the lungs, in addition to the multiple variables added by alterations in its structure and damage inflicted by the inflammatory process, and needs to take into account factors such as aeration of the lungs, deposition and lung function, formation of biofilms and resistance in the face of treatment. [12] and [13]

show abstract

“…It is an approved food additive that has been considered for pharmaceutical formulation and drug delivery applications, in which attention has been focused on its absorption-enhancing, controlled release and bioadhesive properties. Recently, chitosan-based delivery systems have been proposed to increase the bioavailability of drugs both at the nasal mucosa and in the lungs [19,20]; also these systems have been reported as efficient vehicles for pulmonary gene delivery [21][22][23]. Nevertheless chitosan is not included in the FDA Inactive Ingredient Guide and very sparse data on its pulmonary toxicity are available.…”

Section: Introductionmentioning

confidence: 99%

Preparation and In Vitro Evaluation of Budesonide Spray Dried Microparticles for Pulmonary Delivery

Naikwade

2009

Sci. Pharm.

View full text Add to dashboard Cite

The present study describes development and in vitro evaluation of budesonide microparticles prepared by spray drying for delivering drug directly to lungs via dry powder inhaler. This paper introduces new formulations for pharmaceutical applications which includes conventional formulations and novel spray dried microparticles viz., pulmosols, microspheres and porous particles. Optimized spray drying parameters for generation of microparticles were: inlet temperature, 130 °C; outlet temperature, 80 °C; aspirator rate, 240 mWc (60%); solution feed rate, 2 ml/min; spraying air flow pressure, 2 bar. Microparticles appeared to be spherical, low-density particles characterized by smooth surface. MMAD and GSD ranged from 2.5-4.6 µm and 1.5-2.7 respectively. Effective index of microspheres (54.48) and porous particle formulations (64.22) was higher than the conventional formulation (49.21) indicating more effective deposition of microparticles to the lungs. Carr's Index (20-30%) and Hausner ratio (1.2-1.7) for all formulations indicated good powder flow properties. Formulations emitted a fine particle fraction of 25-47%. Microparticles showed extended in vitro drug release upto 4 hours with high respirable fractions, thus use of microparticles potentially offers sustained release profile along with improved delivery of drug to the pulmonary tract.

show abstract

Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis

Cited by 176 publications

References 33 publications

The effects of chitosan oligosaccharide on the activation of murine spleen CD11c+ dendritic cells via Toll-like receptor 4

The effects of chitosan oligosaccharide on the activation of murine spleen CD11c+ dendritic cells via Toll-like receptor 4

Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells

Preparation and In Vitro Evaluation of Budesonide Spray Dried Microparticles for Pulmonary Delivery

Contact Info

Product

Resources

About